ESOPEC trial

• NEJM 2025
• ESOPEC, page 1
• Methods
  • RCT - FLOT4 vs CROSS Trial
  • Inclusion: cT1 cN+, cT2–4a cN+, or cT2–4a cN0 disease
    • Excluded T1 N0, T4b
  • Primary end point overall survival
• Results
  • FLOT4: 221 and CORSS 217 patients
  • 3 year
    • OS 57% FLOT vs 50% CROSS - HR 0.7 for death
    • Progression free survival - 51% FLOT, 35% CROSS
  • Adverse event (g3 or above) 58% FLOT vs 50% CROSS
  • Mortality 3.1% FLOT vs 5.6% CROSS
• Conclusion
  • FLOT led to improved survival